Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

Ketamine modulates theta and gamma oscillations.

Lazarewicz MT, Ehrlichman RS, Maxwell CR, Gandal MJ, Finkel LH, Siegel SJ.

J Cogn Neurosci. 2010 Jul;22(7):1452-64. doi: 10.1162/jocn.2009.21305.

PMID:
19583475
2.

[Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].

Mechri A, Saoud M, Khiari G, d'Amato T, Dalery J, Gaha L.

Encephale. 2001 Jan-Feb;27(1):53-9. Review. French.

PMID:
11294039
3.

The NMDA antagonist model for schizophrenia: promise and pitfalls.

Abi-Saab WM, D'Souza DC, Moghaddam B, Krystal JH.

Pharmacopsychiatry. 1998 Jul;31 Suppl 2:104-9. Review.

PMID:
9754841
4.

Models of schizophrenia in humans and animals based on inhibition of NMDA receptors.

Bubeníková-Valesová V, Horácek J, Vrajová M, Höschl C.

Neurosci Biobehav Rev. 2008 Jul;32(5):1014-23. doi: 10.1016/j.neubiorev.2008.03.012. Epub 2008 Apr 8. Review.

PMID:
18471877
5.

Contribution of AMPA and NMDA receptors to excitatory responses in the inferior colliculus.

Kelly JB, Zhang H.

Hear Res. 2002 Jun;168(1-2):35-42. Review.

PMID:
12117507
6.

Glutamatergic aspects of schizophrenia.

Tamminga C.

Br J Psychiatry Suppl. 1999;(37):12-5. Review.

PMID:
10211134
7.
8.

[Effects of ketamine on CNS-function].

Detsch O, Kochs E.

Anaesthesist. 1997 Mar;46 Suppl 1:S20-9. Review. German.

PMID:
9163274
10.

A systematic review of the effects of NMDA receptor antagonists on oscillatory activity recorded in vivo.

Hunt MJ, Kasicki S.

J Psychopharmacol. 2013 Nov;27(11):972-86. doi: 10.1177/0269881113495117. Epub 2013 Jul 17. Review.

PMID:
23863924
11.

Ketamine and phencyclidine: the good, the bad and the unexpected.

Lodge D, Mercier MS.

Br J Pharmacol. 2015 Sep;172(17):4254-76. doi: 10.1111/bph.13222. Epub 2015 Jul 28. Review.

12.

NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.

Krystal JH, D'Souza DC, Mathalon D, Perry E, Belger A, Hoffman R.

Psychopharmacology (Berl). 2003 Sep;169(3-4):215-33. Epub 2003 Sep 2. Review.

PMID:
12955285
13.

Reviewing the ketamine model for schizophrenia.

Frohlich J, Van Horn JD.

J Psychopharmacol. 2014 Apr;28(4):287-302. doi: 10.1177/0269881113512909. Epub 2013 Nov 20. Review.

14.

Impact of ketamine on neuronal network dynamics: translational modeling of schizophrenia-relevant deficits.

Kocsis B, Brown RE, McCarley RW, Hajos M.

CNS Neurosci Ther. 2013 Jun;19(6):437-47. doi: 10.1111/cns.12081. Epub 2013 Apr 24. Review.

15.

Region-specific changes in gamma and beta2 rhythms in NMDA receptor dysfunction models of schizophrenia.

Roopun AK, Cunningham MO, Racca C, Alter K, Traub RD, Whittington MA.

Schizophr Bull. 2008 Sep;34(5):962-73. doi: 10.1093/schbul/sbn059. Epub 2008 Jun 9. Review.

Supplemental Content

Support Center